| Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI) B Assmus, V Schachinger, C Teupe, M Britten, R Lehmann, N Döbert, ... Circulation 106 (24), 3009-3017, 2002 | 3292 | 2002 |
| Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised … MJ Rummel, N Niederle, G Maschmeyer, GA Banat, U von Grünhagen, ... The Lancet 381 (9873), 1203-1210, 2013 | 1695 | 2013 |
| Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL H Kantarjian, F Giles, L Wunderle, K Bhalla, S O'Brien, B Wassmann, ... New England Journal of Medicine 354 (24), 2542-2551, 2006 | 1648 | 2006 |
| Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 MG Ott, M Schmidt, K Schwarzwaelder, S Stein, U Siler, U Koehl, H Glimm, ... Nature medicine 12 (4), 401-409, 2006 | 1399 | 2006 |
| Targeted therapy with the T-cell–engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results … MS Topp, P Kufer, N Gökbuget, M Goebeler, M Klinger, S Neumann, ... Journal of clinical oncology 29 (18), 2493-2498, 2011 | 1048 | 2011 |
| Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease S Stein, MG Ott, S Schultze-Strasser, A Jauch, B Burwinkel, A Kinner, ... Nature medicine 16 (2), 198-204, 2010 | 917 | 2010 |
| A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias OG Ottmann, BJ Druker, CL Sawyers, JM Goldman, J Reiffers, RT Silver, ... Blood, The Journal of the American Society of Hematology 100 (6), 1965-1971, 2002 | 729 | 2002 |
| Phase II trial of the anti-CD19 bispecific T cell–engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute … MS Topp, N Gökbuget, G Zugmaier, P Klappers, M Stelljes, S Neumann, ... Journal of Clinical Oncology 32 (36), 4134-4140, 2014 | 692 | 2014 |
| Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia M Brüggemann, T Raff, T Flohr, N Gökbuget, M Nakao, J Droese, ... Blood 107 (3), 1116-1123, 2006 | 658 | 2006 |
| Modern therapy of acute lymphoblastic leukemia R Bassan, D Hoelzer Journal of clinical oncology 29 (5), 532-543, 2011 | 655 | 2011 |
| Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma MJ Rummel, SE Al-Batran, SZ Kim, M Welslau, R Hecker, ... Journal of Clinical Oncology 23 (15), 3383-3389, 2005 | 573 | 2005 |
| Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL MS Topp, N Gökbuget, G Zugmaier, E Degenhard, ME Goebeler, ... Blood, The Journal of the American Society of Hematology 120 (26), 5185-5187, 2012 | 546 | 2012 |
| Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies N Gökbuget, M Kneba, T Raff, H Trautmann, CR Bartram, R Arnold, ... Blood, The Journal of the American Society of Hematology 120 (9), 1868-1876, 2012 | 535 | 2012 |
| Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab M Klinger, C Brandl, G Zugmaier, Y Hijazi, RC Bargou, MS Topp, ... Blood, The Journal of the American Society of Hematology 119 (26), 6226-6233, 2012 | 532 | 2012 |
| Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation N Gökbuget, D Stanze, J Beck, H Diedrich, HA Horst, A Hüttmann, ... Blood, The Journal of the American Society of Hematology 120 (10), 2032-2041, 2012 | 485 | 2012 |
| Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia F Thol, F Damm, A Lüdeking, C Winschel, K Wagner, M Morgan, H Yun, ... Journal of Clinical Oncology 29 (21), 2889-2896, 2011 | 483 | 2011 |
| Modelling the risk of adult T‐cell leukemia/lymphoma in persons infected with human T‐lymphotropic virus type I EL Murphy, B Hanchard, JP Figueroa, WN Gibbs, WS Lofters, M Campbell, ... International journal of cancer 43 (2), 250-253, 1989 | 478 | 1989 |
| Treatment of adult acute lymphoblastic leukemia N Gökbuget, D Hoelzer Seminars in hematology 46 (1), 64-75, 2009 | 462 | 2009 |
| Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) B Wassmann, H Pfeifer, N Goekbuget, DW Beelen, J Beck, M Stelljes, ... Blood 108 (5), 1469-1477, 2006 | 461 | 2006 |
| High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome L Bergmann, C Miething, U Maurer, J Brieger, T Karakas, E Weidmann, ... Blood, The Journal of the American Society of Hematology 90 (3), 1217-1225, 1997 | 459 | 1997 |
